<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872391</url>
  </required_header>
  <id_info>
    <org_study_id>EK 017/2009</org_study_id>
    <nct_id>NCT00872391</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma</brief_title>
  <official_title>Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of hypofractionated
      stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for
      the planning target volume (PTV) in patients with uveal melanoma. Patients will be
      followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity,
      secondary complications and survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local tumor control (tumor dimensions; secondary complications; visual acuity; survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>histological assessment of the fraction of living cells in eyes requiring secondary enucleation</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Hypofractionated LINAC radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated linear accelerator radiotherapy</intervention_name>
    <description>10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.</description>
    <arm_group_label>Hypofractionated LINAC radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The initial height of the melanoma is 7 mm or higher.

          -  Juxtapapillary and/or juxtamacular melanomas with a height of 3 mm or higher and if
             the central tumor distance to the optic disc and/or the macula is 3 mm or less.

          -  If other forms of conservative treatment of the melanoma are not possible.

        Exclusion Criteria:

          -  Prior/Concomitant Treatment.

          -  Extrascleral tumor extension is present.

          -  If the presence of neovascular glaucoma is detected before treatment.

          -  If metastasis is detected at baseline.

          -  Previous participation in any study of investigational drugs within 3 month preceding
             day 0.

          -  Pregnant women are not allowed to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Zehetmayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Medical University of Vienna, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Zehetmayer, MD</last_name>
    <phone>+431 40400</phone>
    <phone_ext>7941</phone_ext>
    <email>martin.zehetmayer@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Dieckmann, MD</last_name>
    <phone>+431 40400</phone>
    <phone_ext>2709</phone_ext>
    <email>karin.dieckmann@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophthalmology and the Department of Radiotherapy and Radiobiology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Zehetmayer, MD</last_name>
      <phone>+431 40400</phone>
      <phone_ext>7941</phone_ext>
      <email>martin.zehetmayer@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>March 30, 2009</last_update_submitted>
  <last_update_submitted_qc>March 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Univ. Prof. Dr. Martin Zehetmayer</name_title>
    <organization>Medical University of Vienna</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

